Skip to main content
Kangmei Pharmaceutical Co.,Ltd logo

Kangmei Pharmaceutical Co.,Ltd — Investor Relations & Filings

Ticker · 600518 ISIN · CNE0000017M1 LEI · 3003006FRNBUUTVKBB50 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,369 across all filing types
Latest filing 2025-12-10 Governance Information
Country CN China
Listing Shanghai Stock Exchange 600518

About Kangmei Pharmaceutical Co.,Ltd

http://www.kangmei.com.cn

Kangmei Pharmaceutical Co.,Ltd. focuses on the research, development, production, and distribution of Traditional Chinese Medicine (TCM). The company manages an integrated industry chain that includes herbal cultivation, standardized processing of decoction pieces, and the manufacturing of patent medicines. Its offerings extend to health supplements, medical devices, and functional foods. A key component of its operations is the management of large-scale TCM trading centers and logistics hubs designed to standardize the trade of medicinal materials. Through its "Internet + Healthcare" initiatives, the company provides digital health management and pharmaceutical supply chain services, catering to medical institutions, retail pharmacies, and individual consumers.

Recent filings

Filing Released Lang Actions
康美药业股份有限公司章程（2025年12月）
Governance Information Classification · 95% confidence The document is a detailed company charter or articles of association (章程) for 康美药业股份有限公司, revised in December 2025. It includes comprehensive governance rules, shareholder rights, board structure, share issuance and transfer rules, meeting procedures, and other corporate governance matters. It is not a financial report, earnings release, or announcement but a governance document outlining internal rules and company structure. This matches the description of Governance Information (CGR). The document length is substantial and contains detailed governance provisions, not just an announcement or summary.
2025-12-10 Chinese
康美药业关于独立董事辞职暨补选独立董事的公告
Board/Management Information Classification · 95% confidence The document is an announcement from 康美药业股份有限公司 regarding the resignation of an independent director and the nomination of a new independent director. It details the resignation circumstances, the impact on the board, and the nomination process for the replacement director. There is no financial data, earnings information, or report publication mentioned. The content focuses on changes in the company's board of directors, which fits the category of Board/Management Information (MANG). The document length is short and it is not a report or announcement of a report publication, so it is not RPA or RNS. Therefore, the correct classification is MANG with high confidence.
2025-12-10 Chinese
康美药业股份有限公司会计师事务所选聘制度（2025年12月）
Governance Information Classification · 95% confidence The document is a detailed internal policy document titled '康美药业股份有限公司 会计师事务所选聘制度' which translates to 'Kangmei Pharmaceutical Co., Ltd. Auditor Selection System'. It outlines the procedures, requirements, and governance related to the selection, appointment, and supervision of the company's external audit firm. It references relevant laws and regulations, internal governance, and audit committee responsibilities. There is no financial data, audit report, or financial statements included. It is not an audit report itself but a governance document about auditor selection and oversight. This fits best under Governance Information (CGR), which covers internal rules, board structure, and governance practices. The document length is over 5,000 characters and contains substantive governance content, not a mere announcement or certification. Therefore, the classification is CGR with high confidence.
2025-12-10 Chinese
康美药业股份有限公司对外投资管理制度（2025年12月）
Governance Information Classification · 95% confidence The document is titled '康美药业股份有限公司 对外投资管理制度' which translates to 'Kangmei Pharmaceutical Co., Ltd. External Investment Management System'. It is a detailed internal policy document outlining the principles, approval authorities, organizational structure, management procedures, financial management, auditing, reporting, and disclosure obligations related to the company's external investments. The content is focused on governance and management rules rather than financial results, earnings, or regulatory announcements. There is no indication that this is a report, announcement, or transcript. It is a governance-related internal rules document. Therefore, the most appropriate classification is Governance Information (CGR). The document length (6032 characters) and detailed procedural content support this classification with high confidence.
2025-12-10 Chinese
康美药业股份有限公司独立董事候选人声明与承诺（余宇莹）
Board/Management Information Classification · 95% confidence The document is a declaration and commitment statement by an independent director candidate of 康美药业股份有限公司. It details the candidate's qualifications, compliance with regulatory requirements, and commitment to fulfill the duties of an independent director. There is no financial data, no report or announcement of financial results, no voting results, no management changes, or other typical financial or regulatory filings. This document is a formal statement related to board/management information, specifically about a director candidate's qualifications and commitments. Therefore, it fits best under Board/Management Information (MANG). The document length is short and it is not an announcement of a report publication, so it is not RPA or RNS.
2025-12-10 Chinese
康美药业股份有限公司对外担保管理制度（2025年12月）
Governance Information Classification · 95% confidence The document is titled as a management system for external guarantees by 康美药业股份有限公司. It details internal rules, approval authorities, organizational responsibilities, qualifications for guarantee recipients, information disclosure, and legal responsibilities related to the company's external guarantee activities. There is no indication of financial statements, audit results, earnings data, or shareholder meeting materials. The content is focused on governance and internal control policies regarding external guarantees. Therefore, it fits best under Governance Information (CGR), which covers reports detailing the company's internal rules and governance practices.
2025-12-10 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.